Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS

References

• Barzi, M., et al. 2017. A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism. Nature communications, 8 (1), 39.
   PubMed Web of Science ®Google Scholar
• Bi, Y., et al. 2016. A whole-body physiologically based pharmacokinetic model of gefitinib in mice and scale-up to humans. The AAPS journal, 18 (1), 228–238.
   PubMed Web of Science ®Google Scholar
• Cohen, M.A., et al. 2004. United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clinical cancer research, 10 (4), 1212–1218.
   PubMed Web of Science ®Google Scholar
• D’Atri, V., et al. 2018. Adding a new separation dimension to MS and LC-MS: what is the utility of ion mobility spectrometry? Journal of separation science, 41, 20–67.
   PubMed Web of Science ®Google Scholar
• Dhillon, S., 2015. Gefitinib: a review of its use in adults with advanced non-small cell lung cancer. Targeted oncology, 10 (1), 153–170.
   PubMed Web of Science ®Google Scholar
• Guan, S., et al. 2019. Development and validation of a sensitive LC-MS/MS method for determination of gefitinib and its major metabolites in human plasma and its application in non-small cell lung cancer patients. Journal of pharmaceutical and biomedical analysis, 172, 364–371.
   PubMed Web of Science ®Google Scholar
• Jones, H.K., et al. 2002. A sensitive assay for ZD1839 (Iressa1) in human plasma by liquid–liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials. Journal of pharmaceutical and biomedical analysis, 29 (1–2), 221–228.
   PubMed Web of Science ®Google Scholar
• Letertre, M., et al. 2020. Metabolic phenotyping using UPLC–MS and rapid microbore UPLC–IM–MS: determination of the effect of different dietary regimes on the urinary metabolome of the rat. Chromatographia, 83 (7), 853–861.
   Web of Science ®Google Scholar
• Li, J., et al. 2007. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clinical cancer research, 13 (12), 3731–3737.
   PubMed Web of Science ®Google Scholar
• Liu, X., et al. 2015. Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism. Biochemical pharmacology, 97 (1), 111–121.
   PubMed Web of Science ®Google Scholar
• Maemondo, M., et al. 2010. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New England journal of medicine, 362 (25), 2380–2388.
   PubMed Web of Science ®Google Scholar
• McKillop, D., et al. 2004a. Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. Xenobiotica; the fate of foreign compounds in biological systems, 34 (10), 901–915.
   PubMed Web of Science ®Google Scholar
• McKillop, D., et al. 2004b. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica, 34 (10), 917–934.
   PubMed Web of Science ®Google Scholar
• McKillop, D., et al. 2004c. In vitro metabolism of gefitinib in human liver microsomes. Xenobiotica; the fate of foreign compounds in biological systems, 34 (11–12), 983–1000.
   PubMed Web of Science ®Google Scholar
• Mckillop, D., et al. 2005. Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica; the fate of foreign compounds in biological systems, 35 (1), 39–50.
   PubMed Web of Science ®Google Scholar
• McKillop, D., et al. 2006. Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. Xenobiotica; the fate of foreign compounds in biological systems, 36 (1), 29–39.
   PubMed Web of Science ®Google Scholar
• Nye, L.C., et al. 2019. A comparison of collision cross section values obtained via travelling wave ion mobility-mass spectrometry and ultra high performance liquid chromatography-ion mobility-mass spectrometry: application to the characterisation of metabolites in rat urine. Journal of chromatography A, 1602, 386–396.
   PubMed Web of Science ®Google Scholar
• Rainville, P.D., et al. 2017. Ion mobility spectrometry combined with ultra performance liquid chromatography/mass spectrometry for metabolic phenotyping of urine: effects of column length, gradient duration and ion mobility spectrometry on metabolite detection. Analytica chimica acta, 982, 1–8.
   PubMed Web of Science ®Google Scholar
• Righetti, L., et al. 2018. Ion mobility collision cross section database: application to mycotoxin analysis. Analytica chimica acta, 1014, 50–57.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Suarez, E., et al. 2013. An ion mobility assisted data independent LC-MS strategy for the analysis of complex biological samples. Current analytical chemistry, 9 (2), 199–211.
   Web of Science ®Google Scholar
• Spagou, K., et al. 2011. HILIC-UPLC-MS for exploratory urinary metabolic profiling in toxicological studies. Analytical chemistry, 83 (1), 382–390.
   PubMed Web of Science ®Google Scholar
• Sparidans, R.W., et al. 2016. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. Journal of chromatography. B, analytical technologies in the biomedical and life sciences, 1033–1034, 390–398.
   PubMed Web of Science ®Google Scholar
• Wang, C., et al. 2020. Tentative identification of gefitinib metabolites in non-small-cell lung cancer patient plasma using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry. PLoS One, 15 (7), e0236523.
   PubMed Web of Science ®Google Scholar
• Wang, L.Z., et al. 2011. Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, analytical technologies in the biomedical and life sciences, 879 (22), 2155–2161.
   PubMed Web of Science ®Google Scholar
• Want, E.J., et al. 2010. Global metabolic profiling procedures for urine using UPLC-MS. Nature protocols, 5 (6), 1005–1018.
   PubMed Web of Science ®Google Scholar
• Zhao, M., et al. 2005. Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. Journal of chromatography B, 819 (1), 73–80.
   PubMed Web of Science ®Google Scholar
• Zheng, N., et al. 2016. Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC-MS/MS and its application to a pharmacokinetics study. Journal of chromatography. B, analytical technologies in the biomedical and life sciences, 1011, 215–222.
   PubMed Web of Science ®Google Scholar
• Zhou, X., et al. 2012. Novel liposomal gefitinib (L-GEF) formulations. Anticancer research, 32 (7), 2919–2924.
   PubMed Web of Science ®Google Scholar
• Zhou, Z., et al. 2016. Large-scale prediction of collision cross-section values for metabolites in ion mobility mass spectrometry. Analytical chemistry, 88 (22), 11084–11091.
   PubMed Web of Science ®Google Scholar